Khan Najat's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Aug 19, 2025
- Accession no.
- 0001601830-25-000131
- Filed
- Aug 19, 2025
- Trade date
- Aug 15-18, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $202.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Khan NajatCIK 0002020969 | Director, Officer (Chief R&D Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 15, 2025 | Class A Common Stock | FTax withholdingDisposed | −3,789 | $5.64 | −$21,369.96 | 704,796 | Direct | |
| Aug 18, 2025 | Class A Common Stock | SSaleDisposed | −36,599 | $5.52 | −$202,026.48 | 668,197 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.